Epiregulin enhances tumorigenicity by activating the ERK/MAPK pathway in glioblastoma

Neuro-Oncology

Volumn 16, Issue 7, 2014, Pages 960-970

  Kohsaka, Shinji ^a   Hinohara, Kunihiko ^b   Wang, Lei ^a   Nishimura, Tatsunori ^b   Urushido, Masana ^a   Yachi, Kazuhiro ^a   Tsuda, Masumi ^a   Tanino, Mishie ^a   Kimura, Taichi ^a   Nishihara, Hiroshi ^a   Gotoh, Noriko ^b   Tanaka, Shinya ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

brain tumor; epiregulin; ERK MAPK; GBM

Indexed keywords

ADIPOCYTE ENHANCER BINDING PROTEIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIREGULIN; GEFITINIB; JANUS KINASE; MESSENGER RNA; MICROFIBRILLAR ASSOCIATED PROTEIN 5; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; EREG PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CARCINOGENICITY; COLONY FORMATION; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR REGRESSION; ANIMAL; BAGG ALBINO MOUSE; BRAIN TUMOR; CONFOCAL MICROSCOPY; DNA MICROARRAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOBLOTTING; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; EPIREGULIN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GLIOBLASTOMA; HETEROGRAFTS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, CONFOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84902456310     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not315     Document Type: Article

References (48)

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109.
2. Van Meir EG, Hadjipanayis CG, Norden AD, et al. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin. 2010;60(3):166-193.
3. Mrugala MM, Chamberlain MC. Mechanisms of disease: temozolomide and glioblastoma-look to the future. Nat Clin Pract Oncol. 2008;5(8):476-486.
4. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
5. Network TCGAR. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455(7216):1061-1068.
6. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(3):157-173.
7. Wick W, Weller M, Weiler M, et al. Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro Oncol. 2011; 13(6):566-579.
8. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105-111.
9. Liu K, Lin B, Zhao M, et al. The multiple roles for Sox2 in stem cell maintenance and tumorigenesis. Cell Signal. 2013;25(5): 1264-1271.
10. Lathia JD, Gallagher J, Heddleston JM, et al. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell. 2010;6(5): 421-432.
11. Ogden AT, Waziri AE, Lochhead RA, et al. Identification of A2B5+CD133-tumor-initiating cells in adult human gliomas. Neurosurgery. 2008;62(2):505-514; discussion 514-515.
12. Read TA, Fogarty MP, Markant SL, et al. Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell. 2009;15(2):135-147.
13. Son MJ, Woolard K, Nam DH, et al. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell. 2009;4(5):440-452.
14. Bao S, Wu Q, Li Z, et al. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res. 2008;68(15):6043-6048.
15. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004;64(19):7011-7021.
16. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396-401.
17. Tabu K, Kimura T, Sasai K, et al. Analysis of an alternative human CD133 promoter reveals the implication of Ras/ERK pathway in tumor stem-like hallmarks. Mol Cancer. 2010;9:39.
18. Brescia P, Richichi C, Pelicci G. Current strategies for identification of glioma stem cells: adequate or unsatisfactory? J Oncol. 2012;2012: Article ID 376894.
19. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.
20. Eltarhouny SA, Elsawy WH, Radpour R, et al. Genes controlling spread of breast cancer to lung "gang of 4." Exp Oncol. 2008;30(2):91-95.
21. Komurasaki T, Toyoda H, Uchida D, et al. Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4. Oncogene. 1997;15(23):2841-2848.
22. Inatomi O, Andoh A, Yagi Y, et al. Regulation of amphiregulin and epiregulin expression in human colonic subepithelial myofibroblasts. Int J Mol Med. 2006;18(3):497-503.
23. Gupta GP, Nguyen DX, Chiang AC, et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature. 2007;446(7137):765- 770.
24. Lee D, Pearsall RS, Das S, et al. Epiregulin is not essential for development of intestinal tumors but is required for protection from intestinal damage. Mol Cell Biol. 2004;24(20): 8907-8916.
25. Yun J, Song SH, Park J, et al. Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers. Lab Invest. 2012;92(7):1033-1044.
26. Jin X, Yin J, Kim SH, et al. EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction. Cancer Res. 2011;71(22): 7125-7134.
27. Mazzoleni S, Politi LS, Pala M, et al. Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis. Cancer Res. 2010;70(19):7500-7513.
28. Bleau AM, Hambardzumyan D, Ozawa T, et al. PTEN/PI3 K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell. 2009;4(3): 226-235.
29. Hambardzumyan D, Becher OJ, Rosenblum MK, et al. PI3 K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev. 2008;22(4):436-448.
30. Zhu X, Morales FC, Agarwal NK, et al. Moesin is a glioma progression marker that induces proliferation and Wnt/beta-catenin pathway activation via interaction with CD44. Cancer Res. 2013;73(3): 1142-1155.
31. De Bacco F, Casanova E, Medico E, et al. The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res. 2012;72(17):4537-4550.
32. Guryanova OA, Wu Q, Cheng L, et al. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell. 2011; 19(4):498-511.
33. Sherry MM, Reeves A, Wu JK, et al. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells. 2009;27(10):2383-2392.
34. Ikushima H, Todo T, Ino Y, et al. Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell. 2009;5(5): 504-514.
35. Fassl A, Tagscherer KE, Richter J, et al. Notch1 signaling promotes survival of glioblastoma cells via EGFR-mediated induction of anti-apoptotic Mcl-1. Oncogene. 2012;31(44):4698-4708.
36. Fan X, Khaki L, Zhu TS, et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells. 2010;28(1):5-16.
37. Hinohara K, Kobayashi S, Kanauchi H, et al. ErbB receptor tyrosine kinase/NF-kappaB signaling controls mammosphere formation in human breast cancer. Proc Natl Acad Sci U S A. 2012;109(17): 6584-6589.
38. de Groot JF, Gilbert MR, Aldape K, et al. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol. 2008;90(1):89-97.
39. Peereboom DM, Shepard DR, Ahluwalia MS, et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol. 2010;98(1): 93-99.
40. Prados MD, Chang SM, Butowski N, et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. 2009;27(4):579-584.
41. Reardon DA, Desjardins A, Vredenburgh JJ, et al. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol. 2010;96(2):219-230.
42. van den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC Brain Tumor Group study 26034. J Clin Oncol. 2009;27(8):1268-1274.
43. Thiessen B, Stewart C, Tsao M, et al. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol. 2010;65(2):353-361.
44. He GP, Muise A, Li AW, et al. A eukaryotic transcriptional repressor with carboxypeptidase activity. Nature. 1995;378(6552):92-96.
45. Ro HS, Roncari DA. The C/EBP-binding region and adjacent sites regulate expression of the adipose P2 gene in human preadipocytes. Mol Cell Biol. 1991;11(4):2303-2306.
46. Ladha J, Sinha S, Bhat V, et al. Identification of genomic targets of transcription factor Aebp1 and its role in survival of glioma cells. Mol Cancer Res. 2012;10(8):1039-1051.
47. Akagi T, Sasai K, Hanafusa H. Refractory nature of normal human diploid fibroblasts with respect to oncogene-mediated transformation. Proc Natl Acad Sci U S A. 2003;100(23): 13567-13572.
48. Kohsaka S, Sasai K, Takahashi K, et al. A population of BJ fibroblasts escaped from Ras-induced senescence susceptible to transformation. Biochem Biophys Res Commun. 2011;410(4):878-884.